Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Tolerability of Palonosetron and Dexamethasone Plus Fosaprepitant or Placebo in Patients Receiving Radiotherapy and Weekly Cisplatin.
Brief Summary: GAND-emesis is a multinational, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and tolerability of a neurokinin1 receptor antagonist (fosaprepitant dimeglumine) in combination with an antiemetic (anti-nausea-and-vomiting) control regimen (palonosetron and dexamethasone) in patients with a gynaecological cancer diagnosis, who are scheduled to receive radiotherapy and weekly chemotherapy.

The study aims at investigating if a three-drug antiemetic regimen is superior to a two-drug regimen (standard treatment) in preventing nausea and vomiting in patients receiving radiotherapy and weekly chemotherapy. A pilot study demonstrated that approximately 50% of patients will experience nausea and vomiting when offered a two-drug antiemetic regimen, and it is expected that addition of a third drug (a neurokinin1 receptor antagonist) can increase the proportion of patients with no vomiting in the course of combined chemo-radiotherapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: fosaprepitant dimeglumine, Drug: Dexamethasone, Drug: Ondansetron | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Aprepitant, Drug: Dexamethasone, Drug: Ondansetron | Intervention Type: DRUG; Name: Comparator: fosaprepitant dimeglumine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Aprepitant; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): 1, 2
B: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Placebo, Drug: Ondansetron | Arm Label: Single Dose IV; Type: EXPERIMENTAL; Interventions: Drug: Casopitant, Drug: Dexamethasone, Drug: Ondansetron | Intervention Type: DRUG; Name: Casopitant; Assigned to Arm(s): Single Dose IV | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Control, Single Dose IV | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Control, Single Dose IV
C: Arm Label: Fosaprepitant dimeglumine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fosaprepitant dimeglumine | Arm Label: Saline water; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fosaprepitant dimeglumine; Assigned to Arm(s): Fosaprepitant dimeglumine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Saline water
D: Arm Label: SCH 619734 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: SCH 619734 Dose 1 | Arm Label: SCH 619734 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: SCH 619734 Dose 2 | Arm Label: SCH 619734 Dose 3; Type: EXPERIMENTAL; Interventions: Drug: SCH 619734 Dose 3 | Arm Label: SCH 619734 Dose 4; Type: EXPERIMENTAL; Interventions: Drug: SCH 619734 Dose 4 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SCH 619734 Dose 1; Assigned to Arm(s): SCH 619734 Dose 1 | Intervention Type: DRUG; Name: SCH 619734 Dose 2; Assigned to Arm(s): SCH 619734 Dose 2 | Intervention Type: DRUG; Name: SCH 619734 Dose 3; Assigned to Arm(s): SCH 619734 Dose 3 | Intervention Type: DRUG; Name: SCH 619734 Dose 4; Assigned to Arm(s): SCH 619734 Dose 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C